

Daniela Pugliese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1403887/publications.pdf>

Version: 2024-02-01

62
papers

1,582
citations

257101

24
h-index

329751

37
g-index

62
all docs

62
docs citations

62
times ranked

2414
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. <i>Digestive and Liver Disease</i> , 2022, 54, 440-451.	0.4	22
2	Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the <scp>IG–IBD LIVE</scp> study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 95-109.	1.9	25
3	Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211022.	1.4	7
4	Patient-Reported Outcomes for the Assessment of Sexual Health Among Patients Affected by Inflammatory Bowel Disease. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 250-258.	0.4	0
5	Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 335-339.	0.6	37
6	Two–year effectiveness and safety of golimumab in ulcerative colitis: An IG–IBD study. <i>United European Gastroenterology Journal</i> , 2021, 9, 102-109.	1.6	8
7	Long–term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. <i>United European Gastroenterology Journal</i> , 2021, 9, 507-516.	1.6	11
8	Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 97-104.	1.4	3
9	Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110066.	1.4	34
10	Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2021, 10, 853.	1.0	22
11	Effectiveness of Third-Class Biologic Treatment in Crohn–s Disease: A Multi-Center Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2914.	1.0	8
12	Editorial: withdrawal of anti TNF–alpha –are we ready for biological therapy cycling?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 84-85.	1.9	3
13	Combination therapy in inflammatory bowel disease “ from traditional immunosuppressors towards the new paradigm of dual targeted therapy. <i>Autoimmunity Reviews</i> , 2021, 20, 102832.	2.5	34
14	Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. <i>Digestive and Liver Disease</i> , 2021, , .	0.4	2
15	Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach. <i>Italian Journal of Pediatrics</i> , 2021, 47, 18.	1.0	12
16	Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. <i>Current Medical Research and Opinion</i> , 2020, 36, 7-8.	0.9	5
17	Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. <i>Digestive and Liver Disease</i> , 2020, 52, 44-50.	0.4	7
18	Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e134-e136.	0.9	6

#	ARTICLE	IF	CITATIONS
19	The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When "non-urgent" does not mean "deferable". <i>Digestive and Liver Disease</i> , 2020, 52, 1238-1240.	0.4	4
20	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. <i>United European Gastroenterology Journal</i> , 2020, 8, 1228-1235.	1.6	16
21	The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1306-1314.	0.9	35
22	Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis. <i>United European Gastroenterology Journal</i> , 2020, 8, 11-12.	1.6	5
23	Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre. <i>United European Gastroenterology Journal</i> , 2020, 8, 775-781.	1.6	40
24	Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 65, 280-290.	2.2	4
25	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 568-579.	0.9	51
26	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. <i>Digestive and Liver Disease</i> , 2019, 51, 972-977.	0.4	25
27	Comment on: Emergence of severe spondyloarthritis-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. <i>Rheumatology</i> , 2019, 58, 1113-1115.	0.9	9
28	Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease "AGED" study. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1361-1369.	0.8	14
29	Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2019, 7, 1189-1197.	1.6	31
30	Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2019, 51, 510-515.	0.4	18
31	The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 967-969.	1.4	0
32	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , 2018, 35, 545-562.	1.3	16
33	Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	0.7	7
34	The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 941-950.	1.9	24
35	Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. <i>RMD Open</i> , 2018, 4, e000667.	1.8	15
36	Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2442-2451.	0.9	56

#	ARTICLE	IF	CITATIONS
37	Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. Expert Review of Clinical Immunology, 2018, 14, 751-759.	1.3	14
38	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. Journal of Crohn's and Colitis, 2018, 12, 1079-1088.	0.6	50
39	Anti TNF- $\hat{\pm}$ therapy for ulcerative colitis: current status and prospects for the future. Expert Review of Clinical Immunology, 2017, 13, 223-233.	1.3	78
40	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". Digestive and Liver Disease, 2017, 49, 17-23.	0.4	35
41	Frontiers in Drug Research and Development for Inflammatory Bowel Disease. Frontiers in Pharmacology, 2017, 8, 400.	1.6	40
42	Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug, Healthcare and Patient Safety, 2016, 8, 1.	1.0	3
43	Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission. Inflammatory Bowel Diseases, 2016, 22, 2886-2893.	0.9	42
44	What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 387.	0.6	6
45	Management of perianal fistulas in Crohn's disease: An up-to-date review. World Journal of Gastroenterology, 2015, 21, 1394.	1.4	82
46	Therapeutic drug monitoring of anti-TNF- $\hat{\pm}$ agents in inflammatory bowel diseases. Expert Opinion on Biological Therapy, 2015, 15, 1107-1117.	1.4	13
47	Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis. Inflammatory Bowel Diseases, 2014, 20, 1368-1374.	0.9	55
48	342 Retreatment With Infliximab in Inflammatory Bowel Disease: Tolerability and Effectiveness of Different Re-Induction Regimens. Gastroenterology, 2014, 146, S-78-S-79.	0.6	1
49	Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor $\hat{\pm}$ agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. Digestive and Liver Disease, 2014, 46, 974-979.	0.4	64
50	Reply to Managing Patients with Ulcerative Colitis with Infliximab in Primary and Referral Gastroenterology Centers. Inflammatory Bowel Diseases, 2014, 20, E25.	0.9	0
51	Anti-TNF alpha in the treatment of ulcerative colitis: A valid approach for organ-sparing or an expensive option to delay surgery?. World Journal of Gastroenterology, 2014, 20, 4839.	1.4	22
52	Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: An open-label pilot study. Journal of Crohn's and Colitis, 2013, 7, e623-e629.	0.6	85
53	Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor- $\hat{\pm}$ agents. Journal of Crohn's and Colitis, 2013, 7, 113-119.	0.6	68
54	Adalimumab in active ulcerative colitis: A "real-life" observational study. Digestive and Liver Disease, 2013, 45, 738-743.	0.4	72

#	ARTICLE	IF	CITATIONS
55	FOXP3 ⁺ T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF \pm Agents. <i>BioMed Research International</i> , 2013, 2013, 1-10.	0.9	31
56	Infliximab in Steroid-dependent Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1065-1072.	0.9	66
57	Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab. <i>Drug Design, Development and Therapy</i> , 2013, 7, 289.	2.0	8
58	Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2013, 22, 21-5.	0.5	13
59	Ileal Crohn's disease: CEUS determination of activity. <i>Abdominal Imaging</i> , 2012, 37, 359-368.	2.0	21
60	Adalimumab for ulcerative colitis "is the glass half empty or half full?". <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 249-251.	8.2	2
61	Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. <i>International Journal of Colorectal Disease</i> , 2011, 26, 1435-1444.	1.0	66
62	Update on the management of inflammatory bowel disease: specific role of adalimumab. <i>Clinical and Experimental Gastroenterology</i> , 2011, 4, 163.	1.0	29